Table 3.
Pharmacokinetic Parameters of REG After Oral Administration of Various Niosomal Formulations to Rats (n=6, Mean ± SD)
| Formulation | T max(h) | C max(ng/mL) | AUC0→∞(ng⋅h/mL) | MRT (h) | FRa(%) |
|---|---|---|---|---|---|
| Suspension (Susp) |
0.5 ± 0.0 | 354.2 ± 26.3 | 1384 ± 266 | 3.8 ± 0.3 | —– |
| T80 | 0.8 ± 0.1*** | 1414.0 ± 247.3*** | 3832 ± 505*** | 6.1 ± 0.2*** | 2.77 |
| S60 | 0.8 ± 0.0*** | 520.5 ± 103.1** | 1475 ± 183 | 4.2 ± 0.5 | 1.07 |
| B35 | 0.7 ± 0.1** | 760.1 ± 102.1*** | 2021 ± 232** | 3.3 ± 0.4 | 1.46 |
| TP | 0.8 ± 0.0*** | 778.5 ± 90.3*** | 2654 ± 438*** | 4.6 ± 0.5* | 1.92 |
| M52 | 0.7 ± 0.1** | 634.1 ± 34.0*** | 2372 ± 608* | 4.1 ± 0.4 | 1.71 |
Notes: aFR, the relative bioavailability (%) of REG calculated based on the AUC0→∞ of the drug suspension as the reference. *p < 0.05; **p < 0.01 and ***p < 0.001 significant difference compared with oral suspension of REG.
Abbreviations: AUC, area under the drug concentration–time curve; MRT, mean residence time.